186 related articles for article (PubMed ID: 20096514)
21. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.
Modi NB; Wang B; Noveck RJ; Gupta SK
J Clin Pharmacol; 2000 Oct; 40(10):1141-9. PubMed ID: 11028253
[TBL] [Abstract][Full Text] [Related]
22. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
[TBL] [Abstract][Full Text] [Related]
23. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
Brams M; Mao AR; Doyle RL
Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
[TBL] [Abstract][Full Text] [Related]
24. Sustained release methylphenidate: pharmacokinetic studies in ADDH males.
Birmaher B; Greenhill LL; Cooper TB; Fried J; Maminski B
J Am Acad Child Adolesc Psychiatry; 1989 Sep; 28(5):768-72. PubMed ID: 2793805
[TBL] [Abstract][Full Text] [Related]
25. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Patrick KS; González MA; Straughn AB; Markowitz JS
Expert Opin Drug Deliv; 2005 Jan; 2(1):121-43. PubMed ID: 16296740
[TBL] [Abstract][Full Text] [Related]
26. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form.
Tuerck D; Appel-Dingemanse S; Maboudian M; Pommier F; Wang Y; Sedek G
J Clin Pharmacol; 2007 Jan; 47(1):64-9. PubMed ID: 17192503
[TBL] [Abstract][Full Text] [Related]
27. Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry.
Seçilir A; Schrier L; Bijleveld YA; Toersche JH; Jorjani S; Burggraaf J; van Gerven J; Mathôt RA
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 923-924():22-8. PubMed ID: 23454305
[TBL] [Abstract][Full Text] [Related]
28. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
[TBL] [Abstract][Full Text] [Related]
29. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice.
Manjanatha MG; Shelton SD; Dobrovolsky VN; Shaddock JG; McGarrity LG; Doerge DR; Twaddle NW; Lin CJ; Chen JJ; Mattison DR; Morris SM
Environ Mol Mutagen; 2008 Oct; 49(8):585-93. PubMed ID: 18618596
[TBL] [Abstract][Full Text] [Related]
31. Toxicokinetic assessment of methylphenidate (Ritalin) enantiomers in pregnant rats and rabbits.
Bakhtiar R; Tse FL
Biomed Chromatogr; 2004 Jun; 18(5):275-81. PubMed ID: 15236434
[TBL] [Abstract][Full Text] [Related]
32. A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR
Adjei AL; Chaudhary I; Kollins SH; Padilla A
Paediatr Drugs; 2020 Oct; 22(5):561-570. PubMed ID: 32776159
[TBL] [Abstract][Full Text] [Related]
33. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
González MA; Campbell D; Rubin J
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
[TBL] [Abstract][Full Text] [Related]
35. Sweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice.
Marchei E; Papaseit E; Garcia-Algar O; Bilbao A; Farré M; Pacifici R; Pichini S
Drug Test Anal; 2013 Mar; 5(3):191-5. PubMed ID: 22991172
[TBL] [Abstract][Full Text] [Related]
36. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
[TBL] [Abstract][Full Text] [Related]
37. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
Wilens TE; Biederman J; Lerner M;
J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
[TBL] [Abstract][Full Text] [Related]
38. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
39. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
[TBL] [Abstract][Full Text] [Related]
40. Characterization of anxiety-related responses in male rats following prolonged exposure to therapeutic doses of oral methylphenidate.
Britton GB; Bethancourt JA
Pharmacol Biochem Behav; 2009 Oct; 93(4):451-9. PubMed ID: 19540871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
